William D. Turner
Corporate Officer/Principal en VERA THERAPEUTICS, INC. .
Cargos activos de William D. Turner
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
VERA THERAPEUTICS, INC. | Corporate Officer/Principal | 08/01/2023 | - |
Historial de carrera de William D. Turner
Antiguos cargos conocidos de William D. Turner.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
SIERRA ONCOLOGY, INC. | Director Técnico/Científico/I+D | 04/08/2020 | 01/07/2022 |
AIMMUNE THERAPEUTICS, INC. | Corporate Officer/Principal | 01/07/2018 | 01/04/2020 |
Medimmune, Inc. | Consejero General | - | - |
MedImmune Vaccines, Inc.
MedImmune Vaccines, Inc. BiotechnologyHealth Technology MedImmune Vaccines, Inc. develops, manufactures and markets live vaccines. Its developed vaccine is inhaled FluMist. The company is located in Mountain View, CA | Consejero General | - | - |
DYNAVAX TECHNOLOGIES CORPORATION | Consejero General | 01/08/2006 | - |
Formación de William D. Turner.
The California State University | Undergraduate Degree |
Estadísticas
Internacional
Estados Unidos | 8 |
Operativa
General Counsel | 3 |
Corporate Officer/Principal | 2 |
Undergraduate Degree | 1 |
Sectorial
Health Technology | 7 |
Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
DYNAVAX TECHNOLOGIES CORPORATION | Health Technology |
VERA THERAPEUTICS, INC. | Health Technology |
Empresas privadas | 4 |
---|---|
MedImmune Vaccines, Inc.
MedImmune Vaccines, Inc. BiotechnologyHealth Technology MedImmune Vaccines, Inc. develops, manufactures and markets live vaccines. Its developed vaccine is inhaled FluMist. The company is located in Mountain View, CA | Health Technology |
Sierra Oncology, Inc.
Sierra Oncology, Inc. BiotechnologyHealth Technology Sierra Oncology, Inc. was a clinical stage drug development company of therapeutics for the treatment of cancer. The firm focused on advanced targeted therapeutics for the treatment of patients with significant unmet medical needs in hematology and oncology. Its product Momelotinib, a selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a differentiated therapeutic profile in myelofibrosis encompassing robust constitutional symptom improvements. The company was founded in May 2003 and is headquartered in San Mateo, CA. | Health Technology |
Aimmune Therapeutics, Inc.
Aimmune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA. | Health Technology |
Medimmune, Inc. | Health Technology |
- Bolsa de valores
- Insiders
- William D. Turner
- Experiencia